Результаты поиска

Роль оси CXCL12/CXCR4/CXCR7 в когнитивном повреждении, связанном с нейродегенеративными заболеваниями.

Нейродегенеративные заболевания, включая болезнь Альцгеймера (AD), болезнь Паркинсона (PD), множественный склероз (MS) и амиотропический боковой склероз (ALS), характеризуются постепенной нейронной потерей и когнитивным расстройством (CI). Ось Cystine-X-cystine chemokine ligand 12 (CXCL12)/CXC chemokine рецептор типа 4 (CXCR4)/CXC chemokine рецептор типа 7 (CXCR7) стала критическим молекулярным путем развития CI в этих расстройствах. В настоящем обзоре изучается роль этой оси в патогенезе интеллигенции в связи с этими нейродегенеративными заболеваниями, синтезируются имеющиеся данные и ее посл

Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV non-small-cell lung cancer: A retrospective study.

ObjectivesLung cancer is the leading cause of cancer-related deaths worldwide. However, factors associated with the survival of patients with advanced non-small-cell lung cancer (NSCLC) who received only hospice care are largely unclear. In this study, we aimed to determine the prognostic factors correlated with survival in patients with advanced NSCLC who had undergone hospice care only.MethodsA total of 102 patients with recurrent stage III/IV NSCLC after traditional treatment failure were investigated. Survival was measured from the date of enrollment to December 2019 or the time of death.

Резюме

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Keyword Index for Volume 90

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Множественная миелома среди детей и молодых взрослых: систематический обзор литературы.

Множественная миелома (ММ) крайне редко встречается у педиатров и молодых взрослых людей, а ее клинические характеристики, терапевтические стратегии и результаты по-прежнему плохо определены. Этот систематический обзор объединяет все опубликованные случаи MM у пациентов в возрасте ≤ 25 лет, с тем чтобы определить эпидемиологию, представление, лечение и терауптические результаты. В Пубмеде до 31 декабря 2024 года был проведен систематический поиск литературы в целях выявления сообщений о случаях заболевания и серии MM у пациентов ≤ 25 лет. Исключаются статьи, в которых отсутствуют данные по кон

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies.

Metastatic dissemination of solid tumors, a leading cause of cancer-related mortality, underscores the urgent need for enhanced insights into the molecular and cellular mechanisms underlying metastasis, chemoresistance, and the mechanistic backgrounds of individuals whose cancers are prone to migration. The most prevalent signaling cascade governed by multi-kinase inhibitors is the mitogen-activated protein kinase (MAPK) pathway, encompassing the RAS-RAF-MAPK kinase (MEK)-extracellular signal-related kinase (ERK) pathway. RAF kinase is a primary mediator of the MAPK pathway, responsible for th

Vitamin D in the Prevention and Treatment of Oral Cancer: A Scoping Review.

Introduction: Oral cancer is a serious health problem with an increasing incidence worldwide. Researchers have studied the potential anti-cancerous action of vitamin D and its association with several cancers including oral cancer. The purpose of this scoping review is to synthesize the existing literature on the role of vitamin D on oral cancer. Methods: A scoping review of the literature was conducted using the framework developed by Arkey and O'Malley and the PRISMA-ScR guidelines. Nine databases were searched for peer-reviewed human studies published in English that either investigated the

Should oncologists trust cannabinoids?

Cannabis enjoyed a "golden age" as a medicinal product in the late 19th, early 20th century, but the increased risk of overdose and abuse led to its criminalization. However, the 21st century have witnessed a resurgence of interest and a large body of literature regarding the benefits of cannabinoids have emerged. As legalization and decriminalization have spread around the world, cancer patients are increasingly interested in the potential utility of cannabinoids. Although eager to discuss cannabis use with their oncologist, patients often find them to be reluctant, mainly because clinicians

Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.

Myeloproliferative neoplasms (MPNs) are unique hematopoietic stem cell disorders sharing mutations that constitutively activate the signal-transduction pathways involved in haematopoiesis. They are characterized by stem cell-derived clonal myeloproliferation. The key MPNs comprise chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). CML is defined by the presence of the Philadelphia (Ph) chromosome and BCR-ABL1 fusion gene. Despite effective cytoreductive agents and targeted therapy, complete CML/MPN stem cell eradication is r

Drug delivery for age-related bone diseases: From therapeutic targets to common and emerging therapeutic strategies.

With the accumulation of knowledge on aging, people have gradually realized that among the many factors that cause individual aging, the accumulation of aging cells is an essential cause of organ degeneration and, ultimately, age-related diseases. Most cells present in the bone microenvironment gradually age over time, leading to an imbalance of osteogenesis, osteoclastogenesis, adipogenesis, and chondrogenesis. This imbalance contributes to age-related bone loss and the development of age-related bone diseases, such as osteoporosis. Bone aging can prolong the lifespan and delay the developmen

Clinical epigenetics settings for cancer and cardiovascular diseases: real-life applications of network medicine at the bedside.

Despite impressive efforts invested in epigenetic research in the last 50 years, clinical applications are still lacking. Only a few university hospital centers currently use epigenetic biomarkers at the bedside. Moreover, the overall concept of precision medicine is not widely recognized in routine medical practice and the reductionist approach remains predominant in treating patients affected by major diseases such as cancer and cardiovascular diseases. By its' very nature, epigenetics is integrative of genetic networks. The study of epigenetic biomarkers has led to the identification of num

Диффузный глиома полушария, H3 G34-мутант с выраженным периваскулярным проникновением у мужчины среднего возраста: отчет о случае и обзор литературы по случаям среднего и пожилого возраста.

Распространенный глиома полушария (DHG), H3 G34-мутант, является новоопределяемым детским типом опухолей в 2021 классификации WHO опухолей центральной нервной системы (ЦНС). DHG имеют мутации в кодоне 35 гена H3F3A (мутации H3.3 G35R/V) и демонстрируют разнообразные гистопатологические особенности, такие как глиобластомы или эмбриональные опухоли ЦНС. Независимо от гистологической вариации, они демонстрируют однородные иммуногистохимические и молекулярные характеристики: отрицательный Olig2, потеря ATRX, положительный p53 и гипометилированный промотор MGMT. Эти опухоли преимущественно возникаю

Совпадение в полном тексте источника
… DHGs exhibit recurrent and potentially targetable genetic alterations, including activating mutations and amplifications in PDGFRA , as well as various alterations affecting the CDK4/6‐cyclin D‐p16 INK4a ‐Rb cell cycle pathway [ 3 , 12 , 39 ]. …

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia.

Waldenström's macroglobulinemia (WM) remains an incurable malignancy. However, a number of treatment options exist for patients with WM, including alkylating agents, anti-CD20 monoclonal antibodies, and small molecule inhibitors such as proteasome inhibitors and Bruton tyrosine kinase inhibitors (BTKi). The focus of this review is to highlight the role of BTKi in the management of WM. The first BTKi to receive US Food and Drug Administration approval for WM was ibrutinib. Ibrutinib has been extensively studied in both treatment-naïve WM patients and in those with relapsed/refractory disease. T

IFNIKB: база данных типов I интерферонов для исследований антитуморной иммунности.

Тип I интерферон (ИФН-I) представляет собой важный класс цитокинов, способных ингибировать прогрессирование опухоли через механизмы, такие как иммуномодуляция опухолевого микросреды или воздействие на клеточные компоненты. Несмотря на то, что разработаны различные эндогенные и экзогенные терапевтические стратегии ИФН-I, отчеты о нарушении функции иммунных клеток, вызванных усилением сигнала ИФН-I, указывают на то, что оптимальные стратегии еще не установлены. Однако данные по ИФН-I в настоящее время распределены по нескольким публичным базам данных и отсутствуют систематическая интеграция, что

JAK2 Phosphorylation Signals and Their Associated Cytokines Involved in Chronic Rhinosinusitis with Nasal Polyps and Correlated with Disease Severity.

Janus kinase 2 (JAK2) is a member of the JAK family that transduces cytokine-mediated signals via the JAKs/STATs (signal transducer and activator of transcription proteins) pathway, which plays an important role in many inflammatory diseases. This study investigates the association of p-JAK2 and JAK2-associated cytokines from nasal polyp (NP) tissue with disease severity, and evaluates the p-JAK2-mediated STATs in chronic rhinosinusitis (CRS) with NP. Sixty-one CRSwNP patients with nasal polyps undergoing endoscopic sinus surgery were enrolled, while the turbinate tissues from 26 nasal obstruc

A novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclasts.

Despite the recent advances in the treatment of multiple myeloma (MM), MM patients with high-risk cytogenetic changes such as t(4;14) translocation or deletion of chromosome 17 still have extremely poor prognoses. With the goal of helping these high-risk MM patients, we previously developed a novel phthalimide derivative, TC11. Here we report the further characterization of TC11 including anti-myeloma effects in vitro and in vivo, a pharmacokinetic study in mice, and anti-osteoclastogenic activity. Intraperitoneal injections of TC11 significantly delayed the growth of subcutaneous tumors in hu

Characteristics and treatment patterns in patients with multiple myeloma in Japan: A retrospective cohort analysis.

BackgroundApproval of proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies (mAbs), such as daratumumab, has reshaped treatment patterns in patients with multiple myeloma (MM) in Japan. This retrospective study evaluated patient characteristics, treatment patterns, and trends in MM patients using Medical Data Vision, the largest electronic health records database in Japan with anonymous inpatient and outpatient health information.MethodsPatients aged ≥18 years, with ≥2 records of an MM diagnostic and disease code and ≥1 record of MM treatment between 01 April 2008

A thirteen-gene expression signature predicts survival of patients with pancreatic cancer and identifies new genes of interest.

BackgroundCurrently, prognostication for pancreatic ductal adenocarcinoma (PDAC) is based upon a coarse clinical staging system. Thus, more accurate prognostic tests are needed for PDAC patients to aid treatment decisions.Methods and findingsAffymetrix gene expression profiling was carried out on 15 human PDAC tumors and from the data we identified a 13-gene expression signature (risk score) that correlated with patient survival. The gene expression risk score was then independently validated using published gene expression data and survival data for an additional 101 patients with pancreatic

Oleocanthal as a Multifunctional Anti-Cancer Agent: Mechanistic Insights, Advanced Delivery Strategies, and Synergies for Precision Oncology.

Oleocanthal (OC), a secoiridoid phenolic compound exclusive to extra virgin olive oil (EVOO), has emerged as a promising nutraceutical with multifaceted anti-cancer properties. Despite its well-characterized anti-inflammatory and antioxidant effects, the mechanistic breadth and translational potential of OC in oncology remain underexplored and fragmented across the literature. This comprehensive review synthesizes and critically analyzes recent advances in the molecular, pharmacological, and translational landscape of OC's anti-cancer activities, providing an integrative framework to bridge pr

Update in the management of chronic lymphocytic leukemia.

Advances in the treatment of chronic lymphocytic leukemia (CLL) have improved initial overall response (OR) rates, complete response (CR) rates and progression free survival (PFS). Despite these advances, CLL remains incurable with standard therapies. Thus, there remains a need for more effective therapies in both the upfront and relapsed setting, particularly for patients with high-risk cytogenetic abnormalities such as del(11q22) and del(17p13). The 2008 American Society of Hematology (ASH) Annual Meeting featured several presentations which highlighted the ongoing clinical advances in CLL.